ImmunityBio, Inc.（纳斯达克代码：IBRX）近日发布重要临床研究结果，证实其核心产品Anktiva®在与检查点抑制剂联合应用时，可显著激活淋巴细胞活性，针对非小细胞肺癌（NSCLC）患者展现出潜在治疗价值。该突破性发现为肿瘤免疫治疗领域注入了新的科学依据，进一步拓展了联合疗法的应用边界。
研究数据显示，Anktiva®作为一种淋巴细胞刺激剂，能够有效增强免疫系统对癌细胞的识别与攻击能力。当其与检查点抑制剂协同使用时，不仅提升了整体疗效，还可能克服部分患者对单一免疫疗法的耐药问题。这一成果有望为晚期非小细胞肺癌患者提供更个性化和有效的治疗选择。
目前，ImmunityBio正积极推进相关临床方案的优化与后续研究，力求早日将这一创新疗法推向市场，惠及全球患者。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.